NCT00142974View on ClinicalTrials.gov

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

PHASE2TerminatedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Diabetic Gastropathy
Interventions
DRUG

Tegaserod

Trial Locations (1)

4056

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00142974 - Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy | Biotech Hunter | Biotech Hunter